tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Aug 17;10(8):1330.
doi: 10.3390/vaccines10081330.
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
Naif Khalaf Alharbi[SUP] 1 2 [/SUP], Fahad Aljamaan[SUP] 3 [/SUP], Haya A Aljami[SUP] 1 [/SUP], Mohammed W Alenazi[SUP] 1 [/SUP], Hind Albalawi[SUP] 1 [/SUP], Abdulrahman Almasoud[SUP] 1 [/SUP], Fatima J Alharthi[SUP] 1 [/SUP], Esam I Azhar[SUP] 4 5 [/SUP], Tlili Barhoumi[SUP] 1 2 [/SUP], Mohammad Bosaeed[SUP] 1 2 6 [/SUP], Sarah C Gilbert[SUP] 7 [/SUP], Anwar M Hashem[SUP] 8 9 [/SUP]
Affiliations
Abstract
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic pathogen that can transmit from dromedary camels to humans, causing severe pneumonia, with a 35% mortality rate. Vaccine candidates have been developed and tested in mice, camels, and humans. Previously, we developed a vaccine based on the modified vaccinia virus Ankara (MVA) viral vector, encoding a full-length spike protein of MERS-CoV, MVA-MERS. Here, we report the immunogenicity of high-dose MVA-MERS in prime-boost vaccinations in mice and camels.
Methods: Three groups of mice were immunised with MVA wild-type (MVA-wt) and MVA-MERS (MVA-wt/MVA-MERS), MVA-MERS/MVA-wt, or MVA-MERS/MVA-MERS. Camels were immunised with two doses of PBS, MVA-wt, or MVA-MERS. Antibody (Ab) responses were evaluated using ELISA and MERS pseudovirus neutralisation assays.
Results: Two high doses of MVA-MERS induced strong Ab responses in both mice and camels, including neutralising antibodies. Anti-MVA Ab responses did not affect the immune responses to the vaccine antigen (MERS-CoV spike).
Conclusions: MVA-MERS vaccine, administered in a homologous prime-boost regimen, induced high levels of neutralising anti-MERS-CoV antibodies in mice and camels. This could be considered for further development and evaluation as a dromedary vaccine to reduce MERS-CoV transmission to humans.
Keywords: MERS-CoV; MVA; antibody; camel; mice; vaccine; viral vector.
. 2022 Aug 17;10(8):1330.
doi: 10.3390/vaccines10081330.
Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels
Naif Khalaf Alharbi[SUP] 1 2 [/SUP], Fahad Aljamaan[SUP] 3 [/SUP], Haya A Aljami[SUP] 1 [/SUP], Mohammed W Alenazi[SUP] 1 [/SUP], Hind Albalawi[SUP] 1 [/SUP], Abdulrahman Almasoud[SUP] 1 [/SUP], Fatima J Alharthi[SUP] 1 [/SUP], Esam I Azhar[SUP] 4 5 [/SUP], Tlili Barhoumi[SUP] 1 2 [/SUP], Mohammad Bosaeed[SUP] 1 2 6 [/SUP], Sarah C Gilbert[SUP] 7 [/SUP], Anwar M Hashem[SUP] 8 9 [/SUP]
Affiliations
- PMID: 36016218
- DOI: 10.3390/vaccines10081330
Abstract
The Middle East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic pathogen that can transmit from dromedary camels to humans, causing severe pneumonia, with a 35% mortality rate. Vaccine candidates have been developed and tested in mice, camels, and humans. Previously, we developed a vaccine based on the modified vaccinia virus Ankara (MVA) viral vector, encoding a full-length spike protein of MERS-CoV, MVA-MERS. Here, we report the immunogenicity of high-dose MVA-MERS in prime-boost vaccinations in mice and camels.
Methods: Three groups of mice were immunised with MVA wild-type (MVA-wt) and MVA-MERS (MVA-wt/MVA-MERS), MVA-MERS/MVA-wt, or MVA-MERS/MVA-MERS. Camels were immunised with two doses of PBS, MVA-wt, or MVA-MERS. Antibody (Ab) responses were evaluated using ELISA and MERS pseudovirus neutralisation assays.
Results: Two high doses of MVA-MERS induced strong Ab responses in both mice and camels, including neutralising antibodies. Anti-MVA Ab responses did not affect the immune responses to the vaccine antigen (MERS-CoV spike).
Conclusions: MVA-MERS vaccine, administered in a homologous prime-boost regimen, induced high levels of neutralising anti-MERS-CoV antibodies in mice and camels. This could be considered for further development and evaluation as a dromedary vaccine to reduce MERS-CoV transmission to humans.
Keywords: MERS-CoV; MVA; antibody; camel; mice; vaccine; viral vector.